# A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

> **NCT04573192** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Philogen S.p.A.** · enrollment: 142 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** L19TNF
- **DRUG:** Lomustine

## Key facts

- **NCT ID:** NCT04573192
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-19
- **Primary completion:** 2025-03
- **Final completion:** 2025-12
- **Target enrollment:** 142 (ESTIMATED)
- **Last updated:** 2024-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04573192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04573192, "A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04573192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*